Intensive Care Management of Chimeric Antigen Receptor (CAR) T-Cell Therapy-Associated Toxicities
Journal of Clinical Practice and Research · 2026
DOI: 10.14744/dcybd.2026.78404 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Practice and Research, 2026. Verfasst von Gulbin Aygencel und 1 weiteren Autor:innen.
Themen: Intensivpflege
Abstract (Originalsprache)
Aim: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed or refractory hematologic malignancies, offering durable responses in selected patients while introducing unique immune-mediated toxicities that can rapidly become life-threatening and require intensive care management.This narrative review provides an evidence-based, practical overview of CAR T-cell therapy, focusing on the recognition and management of its major complications in clinical and critical care settings.Current evidence on CAR T-cell biology, clinical indications, toxicity grading, diagnostic evaluation, and intensive care management is synthesized, with particular emphasis on cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS).Effective management depends on early recognition, standardized grading, close multidisciplinary collaboration, prompt initiation of immunomodulatory therapy, and timely organ support when indicated.Although the use of CAR T-cell therapy is expanding globally, published clinical experience from Türkiye remains limited, highlighting the need for specialized treatment centers, standardized national protocols, multidisciplinary expertise, and prospective outcome registries.This review provides a practical framework for intensivists caring for patients receiving CAR T-cell therapy, particularly in newly established programs and resource-limited settings, and emphasizes strategies to optimize clinical outcomes through early diagnosis and timely intervention.
Zitieren
APA
Aygencel, G., & Nates, J. L. (2026). Intensive Care Management of Chimeric Antigen Receptor (CAR) T-Cell Therapy-Associated Toxicities. Journal of Clinical Practice and Research. https://doi.org/10.14744/dcybd.2026.78404
Vancouver
Aygencel G, Nates JL. Intensive Care Management of Chimeric Antigen Receptor (CAR) T-Cell Therapy-Associated Toxicities. Journal of Clinical Practice and Research. 2026. doi:10.14744/dcybd.2026.78404
BibTeX
@article{Aygencel2026,
author = {Aygencel, Gulbin and Nates, Joseph L.},
title = {Intensive Care Management of Chimeric Antigen Receptor (CAR) T-Cell Therapy-Associated Toxicities},
journal = {Journal of Clinical Practice and Research},
year = {2026},
doi = {10.14744/dcybd.2026.78404}
}
EUVIMED